

SUPPLEMENTARY TABLE. Effectiveness of mRNA COVID-19 vaccination against COVID-19–associated hospitalization among children and adolescents aged 5–18 years, stratified by vaccination timing during Omicron BA.1 subvariant predominance—the Overcoming COVID-19 Network, 34 pediatric hospitals, 26 states, December 19, 2021–March 19, 2022

Vaccination status	No. Vaccinated / Total no. (%)		Interval from last vaccine dose to hospitalization, days (IQR)	VE against COVID-19–associated hospitalization % (95% CI)
	Case-patients	Control patients		
Among all hospitalized patients				
Any original monovalent dose	150/638 (24)	288/776 (37)	129 (47–198)	55 (38–67)
Received 7–119 days before hospitalization	59/547 (11)	149/637 (23)	46 (27–74)	62 (45–74)
Received 20–364 days before hospitalization	91/579 (16)	139/627 (22)	195 (162–227)	47 (17–66)
Among patients with critical illness	17/118 (14)	48/118 (41)	132 (46–215)	79 (59–89)

Abbreviation: VE = vaccine effectiveness.